Drugs Made In America Acquisition II Corp. Ordinary Shares Financial Flexibility Index
Drugs Made In America Acquisition II Corp. Ordinary Shares financial flexibility index. Drugs Made In America Acquisition II Corp. Ordinary Shares (DMII) has a Financial Flexibility Index of -0.01x as of June 2026. Free cash flow of $-172.75K (operating CF $-172.75K minus capex $0.00) represents 0% of total liabilities ($18.14 Million). Read debt load of Drugs Made In America Acquisition II Cor for a breakdown of total debt and financial obligations.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of Drugs Made In America Acquisition II Corp. Ordinary Shares (2024–2025)
Financial flexibility index of Drugs Made In America Acquisition II Corp. Ordinary Shares from 2024 to 2025. Historical Financial Flexibility Index trend for Drugs Made In America Acquisition II Corp. Ordinary Shares across 2 annual periods. Explore Drugs Made In America Acquisition II Cor cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Drugs Made In America Acquisition II Corp. Ordinary Shares Financial Flexibility Index by Year (2024–2025)
Drugs Made In America Acquisition II Corp. Ordinary Shares financial flexibility index by year from 2024 to 2025. Year-by-year free cash flow to debt coverage for Drugs Made In America Acquisition II Corp. Ordinary Shares. For the full cash flow conversion analysis, see DMII cash generation efficiency.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -0.06x | $-1.02 Million | $-1.02 Million | $17.80 Million | ▲ +92.5% |
| 2024 | -0.76x | $-194.30K | $-194.30K | $254.78K | — |